These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 21307155

  • 1. Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis.
    Jabbar S, Drury J, Fordham JN, Datta HK, Francis RM, Tuck SP.
    J Clin Pathol; 2011 Apr; 64(4):354-7. PubMed ID: 21307155
    [Abstract] [Full Text] [Related]

  • 2. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari SM, Ahmadi E, Movahed A, Moradhaseli F, Sanjdideh Z, Obeidi N, Amiri Z.
    Menopause; 2009 Apr; 16(5):950-5. PubMed ID: 19387415
    [Abstract] [Full Text] [Related]

  • 3. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y, Onouchi T, Ikeda T, Adachi J, Tamura Y, Horiuchi T.
    Gerontology; 2009 Apr; 55(3):275-80. PubMed ID: 19158438
    [Abstract] [Full Text] [Related]

  • 4. Plasma vitamin D and cytokines in periodontal disease and postmenopausal osteoporosis.
    Jabbar S, Drury J, Fordham J, Datta HK, Francis RM, Tuck SP.
    J Periodontal Res; 2011 Feb; 46(1):97-104. PubMed ID: 20731767
    [Abstract] [Full Text] [Related]

  • 5. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R, Muñoz-Torres M, García DF, Mezquita-Raya P, García Salcedo JA, de Dios Luna J.
    Menopause; 2010 Feb; 17(1):140-4. PubMed ID: 19574937
    [Abstract] [Full Text] [Related]

  • 6. The OPG/RANKL system and zinc ions are promoters of bone remodeling by osteoblast proliferation in postmenopausal osteoporosis.
    Gurban CV, Mederle O.
    Rom J Morphol Embryol; 2011 Feb; 52(3 Suppl):1113-9. PubMed ID: 22119834
    [Abstract] [Full Text] [Related]

  • 7. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C, Gourgiotis D, Kossiva L, Doulgeraki A, Marmarinos A, Galli-Tsinopoulou A, Karavanaki K.
    Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
    [Abstract] [Full Text] [Related]

  • 8. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.
    Pietrapertosa AC, Minenna G, Colella SM, Santeramo TM, Renni R, D'Amore M.
    Panminerva Med; 2009 Mar; 51(1):17-23. PubMed ID: 19352306
    [Abstract] [Full Text] [Related]

  • 9. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A.
    Horm Metab Res; 2008 Apr; 40(4):281-5. PubMed ID: 18275008
    [Abstract] [Full Text] [Related]

  • 10. Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn's disease.
    Turk N, Cukovic-Cavka S, Korsic M, Turk Z, Vucelic B.
    Eur J Gastroenterol Hepatol; 2009 Feb; 21(2):159-66. PubMed ID: 19098682
    [Abstract] [Full Text] [Related]

  • 11. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
    D'Amore M, Fanelli M, D'Amore S, Fontana A, Minenna G.
    Panminerva Med; 2006 Dec; 48(4):215-21. PubMed ID: 17215793
    [Abstract] [Full Text] [Related]

  • 12. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.
    Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E.
    Eur J Endocrinol; 2007 May; 156(5):555-62. PubMed ID: 17468191
    [Abstract] [Full Text] [Related]

  • 13. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG, Kim JH, Kim JY, Ku SY, Jee BC, Suh CS, Kim SH, Choi YM.
    Menopause; 2007 May; 14(5):913-8. PubMed ID: 17667143
    [Abstract] [Full Text] [Related]

  • 14. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.
    Monegal A, Navasa M, Peris P, Alvarez L, Pons F, Rodés J, Guañabens N.
    Liver Int; 2007 May; 27(4):492-7. PubMed ID: 17403189
    [Abstract] [Full Text] [Related]

  • 15. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males.
    Oh KW, Rhee EJ, Lee WY, Kim SW, Baek KH, Kang MI, Yun EJ, Park CY, Ihm SH, Choi MG, Yoo HJ, Park SW.
    Clin Endocrinol (Oxf); 2005 Jan; 62(1):92-8. PubMed ID: 15638876
    [Abstract] [Full Text] [Related]

  • 16. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.
    Mezquita-Raya P, de la Higuera M, García DF, Alonso G, Ruiz-Requena ME, de Dios Luna J, Escobar-Jiménez F, Muñoz-Torres M.
    Osteoporos Int; 2005 Nov; 16(11):1368-74. PubMed ID: 15711777
    [Abstract] [Full Text] [Related]

  • 17. Increased formation of 8-iso-prostaglandin F(2alpha) is associated with altered bone metabolism and lower bone mass in hypercholesterolaemic subjects.
    Mangiafico RA, Malaponte G, Pennisi P, Li Volti G, Trovato G, Mangiafico M, Bevelacqua Y, Mazza F, Fiore CE.
    J Intern Med; 2007 Jun; 261(6):587-96. PubMed ID: 17547714
    [Abstract] [Full Text] [Related]

  • 18. Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women.
    Zhao HY, Liu JM, Ning G, Zhao YJ, Chen Y, Sun LH, Zhang LZ, Xu MY, Chen JL.
    Osteoporos Int; 2008 Feb; 19(2):221-6. PubMed ID: 17703270
    [Abstract] [Full Text] [Related]

  • 19. Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis.
    Verit FF, Geyikli I, Yazgan P, Celik A.
    Arch Gynecol Obstet; 2006 Jun; 274(3):133-7. PubMed ID: 16532321
    [Abstract] [Full Text] [Related]

  • 20. Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor κB ligand in the diagnosis of osteoporosis.
    Piatek S, Adolf D, Wex T, Halangk W, Klose S, Westphal S, Amthauer H, Winckler S.
    Maturitas; 2013 Apr; 74(4):363-8. PubMed ID: 23391500
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.